Gene Therapy vs RNAi / siRNA — Neurology Deal Terms Comparison
Market Analysis
In neurology, Gene Therapy and RNAi / siRNA represent two of the most actively transacted modalities. At Phase 2, Gene Therapy deals carry a median total deal value of $3.0B with $331M upfront, compared to $3.5B total value and $395M upfront for RNAi / siRNA. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Gene Therapy development milestones average $874M versus $1.0B for RNAi / siRNA. Commercial milestones are $821M for Gene Therapy and $961M for RNAi / siRNA. Royalty rates range from 12.3%-19.7% for Gene Therapy and 12.9%-20.6% for RNAi / siRNA.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Gene Therapy and RNAi / siRNA deal terms compare in neurology?
Which modality commands higher royalty rates: Gene Therapy or RNAi / siRNA?
How do milestone structures differ between Gene Therapy and RNAi / siRNA?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.